AIkido Pharma Inc. (Nasdaq: AIKI), a US-based biotechnology company, concentrating on developing small-molecule anti-cancer therapeutics, announced on Friday that it has established a wholly owned financial services subsidiary.
The company has set up the subsidiary with the aim of making strategic investments and acquisitions across the fintech and financial services industries. It is intended to be the focus of a long-range plan to diversify the company's business beyond biotechnology, in order to decrease volatility and mitigate risk while increasing revenue and improving shareholder value.
The company said that the new subsidiary is to use the extensive capital markets expertise of the company's board of directors to identify investment opportunities and acquisition targets in wealth management, investment banking, alternative investments, and asset management with the aim of transforming and optimising operations with a synergistic and accretive business model. The firm said that it is in the process of hiring additional top-tier talent to implement the strategy.
Scancell initiates SCOPE trial's iSCIB1+ cohort
Bio-Thera Solutions' BAT8006 phase II Study receives US FDA IND approval
Poseida Therapeutics names new chief medical officer
Biocytogen and ABL Bio collaborate on development of new bispecific antibody-drug conjugates
BioVaxys Technology announces non-brokered private placement
Senhwa Biosciences doses first subject in phase II study of Silmitasertib
Antennova completes first dosing cohort in Phase one study of ATN-031
M8 Pharmaceuticals collaborates with SERB Pharmaceuticals
BerGenBio ASA starts Phase 2a portion of BGBC016 clinical study of bemcentinib
Phanes Therapeutics receives FDA Fast Track designation for PT886